Objective: The optimal treatment for elderly patients with limited-disease small cell lung cancer has not been defined. We therefore performed a Phase I study for split-dose cisplatin plus etoposide combined with early concurrent accelerated hyperfractionated thoracic radiotherapy in elderly (70 years of age or older) patients with limited-disease small cell lung cancer. Methods: Chemotherapy consisted of cisplatin at 20 or 25 mg/m 2 and etoposide at 80 mg/m 2 , both administered on Days 1 -3 of a 28-day cycle. Radiotherapy was initiated at the onset of chemotherapy and administered at a dose of 1.5 Gy twice daily over 3 weeks up to a total dose of 45 Gy. Results: Twelve patients with a median age of 76 years (range, 70 -85) were enrolled. Doselimiting toxicities occurred in two (hyponatremia of Grade 4 or cardiac ischemia of Grade 3) of the six patients treated at dose Level 1 as well as in three ( perforation of the sigmoid colon of Grade 3, febrile neutropenia of Grade 3, or hyponatremia of Grade 3) of the six patients treated at dose Level 2. The most frequent non-hematologic adverse events included anorexia, fatigue, esophagitis and pneumonitis, but most of these events were of Grade 1 or 2. Conclusions: The recommended dose for cisplatin and etoposide chemotherapy administered on Days 1 -3 was determined to be 20 and 80 mg/m 2 , respectively. Our results indicate that split-dose cisplatin plus etoposide chemotherapy combined with early concurrent accelerated hyperfractionated thoracic radiotherapy is well tolerated by elderly patients with limited-disease small cell lung cancer. Clinical trials registration no: UMIN Clinical Trials Registry (UMIN-CTR) C000000143.
INTRODUCTION
Small cell lung cancer (SCLC) accounts for 15% of all lung cancer cases (1, 2) , with 30% of SCLC cases being limiteddisease SCLC (LD-SCLC), which is confined to one hemithorax and its regional lymph nodes and which can be encompassed by a single radiation therapy port. The number of elderly SCLC patients continues to rise with the growing geriatric population, with 50% of individuals with LD-SCLC now being 70 years of age or older (3) . It is thus important to understand the effects of modern combined modality therapy in such elderly patients.
On the basis of the results of several randomized trials, cisplatin and etoposide chemotherapy with early concurrent accelerated hyperfractionated thoracic radiotherapy (ACC HFX TRT) is regarded as the standard treatment for patients with LD-SCLC (4 -7) . Given the lack of data specific to the elderly, however, the optimal treatment for older individuals with LD-SCLC has not been defined to date. Subset analysis of patients with LD-SCLC enrolled in a Phase III study of etoposide and cisplatin chemotherapy with early concurrent TRT showed that hematologic toxicity and treatment-related death occurred much more frequently among individuals aged 70 years or older than among younger patients (6, 8) . Indeed, we previously found a high incidence of leukopenia of Grade 4 (83%) and febrile neutropenia of Grade 3 (67%) among Japanese LD-SCLC patients aged 70 years or older treated with standard doses of cisplatin and etoposide combined with early concurrent ACC HFX TRT (9) . There is thus a growing need to establish new treatment regimens for combination with early concurrent ACC HFX TRT in elderly LD-SCLC patients.
The (10) . Although thrombocytopenia of Grade 3 or 4 occurred more frequently in the CE arm than in the SPE arm (56 vs. 14%, P , 0.01), both regimens were found to be feasible and active, yielding a median overall survival (OS) of 10 months. We have now performed a Phase I study to evaluate dose-limiting toxicity (DLT) and to determine the recommended dose (RD) for SPE chemotherapy combined with early concurrent ACC HFX TRT in elderly (70 years of age or older) patients with LD-SCLC.
PATIENTS AND METHODS

PATIENTS
Eligible patients were required to have histologically or cytologically proven LD-SCLC, defined as disease confined to one hemithorax including bilateral supraclavicular nodes. Other eligibility criteria included no previous chemotherapy or radiotherapy; a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale; an age of 70 years; a life expectancy of at least 12 weeks; adequate bone marrow reserve (leukocyte count of 4000/mm 3 , neutrophil count of 2000/mm 3 , platelet count of 100 000/mm 3 , and hemoglobin concentration of 9 g/dl); normal liver function (total serum bilirubin concentration of 1.5 mg/dl as well as aspartate transaminase and alanine transaminase levels of less than twice the upper limit of the normal range); a 24 h creatinine clearance of 50 ml/min; and a partial pressure of arterial oxygen of 70 torr. Patients were excluded if they had an active additional malignancy; a concomitant serious illness such as uncontrolled angina pectoris; a history of myocardial infarction in the previous 3 months; heart failure; uncontrolled diabetes mellitus; uncontrolled hypertension; interstitial pneumonia or lung disease; or an infection or other condition contraindicating chemotherapy or radiotherapy. The study was approved by the local ethics committee, and written informed consent was obtained from all patients. 
744
Chemoradiotherapy for elderly LD-SCLC patients (V20) should not exceed 35%, and the maximum dose to the spinal cord could not exceed 40 Gy. Thoracic radiotherapy was suspended if any of the following toxicities were noted: leukocyte count of ,1000/mm 3 , neutrophil count of ,500/mm 3 , platelet count of ,25 000/ mm 3 , fever of 388C, esophagitis or dermatitis of Grade 3 or 4, a partial pressure of arterial oxygen of ,60 torr, or suspected radiation pneumonitis.
After chemoradiotherapy, patients were treated with three 28-day cycles of SPE beginning on Day 29. If the leukocyte count fell to ,4000/mm 3 or the platelet count fell below 100 000/mm 3 on the first day of SPE, chemotherapy was withheld until the counts recovered to 4000/mm 3 and 100 000/ mm 3 , respectively. Prophylactic cranial irradiation (25 Gy in 10 fractions) was performed for patients showing a complete response or a near-complete response defined as a reduction of .90% in the sum of the products of the greatest perpendicular dimensions of bidimensional lesions.
DEFINITION OF MAXIMUM TOLERATED DOSE, RD AND DLT
The maximum tolerated dose (MTD) was defined as the dose level at which DLT occurs in .33% of patients treated, with the preceding dose level then being the RD. Three patients were initially enrolled at dose Level 1. If none of the patients experienced DLT, the next cohort of patients was treated at dose Level 2. If one or two patients of the initial cohort experienced DLT, three additional patients were treated at the same dose level. If no more than two of the six patients experienced DLT, the next cohort of patients was treated at dose Level 2. If none to two of the initial three patients experienced DLT at dose Level 2, an additional three patients were treated at this dose level. If fewer than three of the six patients experienced DLT, dose Level 2 was defined as the RD. DLT was defined as any of the following occurring within 90 days after the onset of chemoradiotherapy: (1) neutropenia of Grade 4 persisting for 7 days or longer, (2) febrile neutropenia of Grade 3, (3) a platelet count of ,25 000/mm 3 , (4) non-hematologic toxicity of Grade 3 or 4 other than appetite loss, nausea, or vomiting, or (5) inability to receive the scheduled 45 Gy of TRT within 5 weeks because of adverse events.
SAFETY AND EFFICACY ASSESSMENT
Complete blood cell counts and a serum chemistry profile were determined and a physical examination and chest X-ray were performed at least once a week during treatment. Toxicities were assessed according to Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Objective tumor response was evaluated according to the Response Evaluation Criteria in Solid Tumors. Overall survival time was defined as the interval between the date of treatment initiation and the date either of death due to any cause or of the most recent follow-up evaluation. Progression-free survival (PFS) time was calculated from the date of treatment initiation to the date of detection of disease progression or the date of death from any cause. Survival curves were estimated by the Kaplan-Meier method.
RESULTS
PATIENTS
Twelve patients (10 men, 2 women) were enrolled in the study ( Table 1 ). The median age of the subjects was 76 years (range, Table 1 ) complained of chest pain, and she manifested elevated serum levels of troponin and creatine kinase on Day 9 of Cycle 1. Although emergency cardiac catheterization revealed no specific cardiovascular abnormalities, isosorbide dinitrate and anticoagulant therapy with heparin were initiated and the chest pain subsided. Thoracic radiotherapy was resumed on Day 11 and was completed in 31 days. We considered this event to be cardiac ischemia of Grade 3 and therefore to reflect DLT. Two of the six patients treated at dose Level 1 thus developed DLT ( Table 2 ). The Independent Data and Safety Monitoring Committee reviewed the reports of these results from the investigators and permitted dose escalation to Level 2. At dose Level 2, one ( patient no. 2-2, Table 1 ) of the first three patients developed DLT. The patient had asymptomatic fever with a temperature above 388C and a high serum concentration of C-reactive protein. A whole-body CT scan detected intraperitoneal free air, and emergency surgery was performed with colostomy on Day 17. We considered this event to be perforation of the sigmoid colon of Grade 3 and therefore to reflect DLT, and we discontinued all the protocol treatment. Among the three additional patients treated at dose Level 2, two individuals developed DLT, hyponatremia of Grade 3 on Day 21 of Cycle 1 ( patient no. 2-5, Table 1 ) or febrile neutropenia of Grade 3 on Day 15 of Cycle 1 (patient no. 2-6, Table 1 ). These two patients continued the protocol treatment with a dose reduction for cisplatin to 20 mg/m 2 and for etoposide to 70 mg/m 2 after amelioration of the adverse event, and TRT was completed in 27 and 22 days, respectively. Given that three of six patients experienced DLT at dose Level 2 (Table 2) , this dose was determined as the MTD.
OTHER NON-DLT TOXICITIES
Hematologic and non-hematologic toxicities are summarized in Table 3 . All patients had leukopenia and neutropenia of Grade 3 or 4. The most frequent non-hematologic adverse events were anorexia (11 patients), fatigue (8 patients), and esophagitis (7 patients). Most of these events were of mild-to-moderate intensity and of CTCAE Grade 1 or 2. Radiation pneumonitis of Grade 1 was observed in three and four patients at dose Levels 1 and 2, respectively. Only one patient experienced pneumonitis of Grade 3; the patient, who was treated at dose Level 2, developed deteriorating dyspnea with a dry cough and slight fever and was referred to our hospital 72 days after the last dose of chemotherapy (134 days after the end of TRT). A chest CT scan revealed extensive bilateral ground-glass opacities outside of the radiation field. The patient required supplemental oxygen and received high-dose methylprednisolone treatment, which resulted in amelioration of his symptoms.
TREATMENT DELIVERY
Eleven of 12 patients completed the planned TRT, with the days of irradiation ranging from 20 -31 (median of 26) ( Table 1 ). Eight of these 11 patients experienced a TRT delay, the reasons for which included the development of febrile neutropenia of Grade 3 in one patient, leukopenia and neutropenia of Grade 4 in six patients, and cardiac ischemia of Grade 3 in one patient. Finally, seven patients completed four cycles of chemotherapy. The median number of cycles at dose Levels 1 and 2 was 3 and 4, and the median chemotherapy interval was 28 and 30.5 days, respectively.
OBJECTIVE RESPONSE AND EFFICACY
All patients with the exception of the one who discontinued TRT (patient no. 2-2, Table 1 ) were evaluable for objective response. Four patients showed a complete response and seven showed a partial response. The first relapse site was local recurrence in two patients, whereas distant metastasis was the cause of failure in six patients. Brain metastasis alone as the first site was observed in two patients. At the time of last follow-up, four patients were still alive, two without evidence of relapse. Five patients had died from cancer-related causes, and one died without relapse. Median PFS and median OS were 11.5 and 17.0 months, respectively (Fig. 2) . Chemoradiotherapy for elderly LD-SCLC patients
DISCUSSION
We performed the present study of early concurrent ACC HFX TRT with split-dose cisplatin and etoposide in elderly patients with LD-SCLC in order to determine the MTD for chemotherapy. The MTD for cisplatin and etoposide was found to be 25 mg/m 2 on Days 1 -3 and 80 mg/m 2 on Days 1 -3, respectively.
The major toxic effects in the present study were myelosuppression and neutropenic fever. Previous subset analysis of patients with LD-SCLC enrolled in a Phase III study in which the standard doses of cisplatin (80 mg/m 2 , Day 1) and etoposide (100 mg/m 2 , Days 1 -3) were administered with early concurrent TRT revealed the incidence of hematologic toxicity to be significantly higher in elderly patients than in younger individuals (8) . Indeed, our previous retrospective analysis also revealed a high incidence of leukopenia of Grade 4 (83%) and febrile neutropenia of Grade 3 (67%) in LD-SCLC patients 70 years of age or older treated with standard doses of cisplatin and etoposide combined with early concurrent ACC HFX TRT (9) . In the present study, the incidence of leukopenia of Grade 4 and febrile neutropenia of Grade 3 was reduced to 58% and 33%, respectively. A recent meta-analysis for LD-SCLC patients treated with chemoradiotherapy found that the time between the first day of chemotherapy and the last day of radiotherapy was an important prognostic factor for this condition, with the survival advantage being most pronounced if TRT was completed in ,30 days (11) . In our study, 11 of 12 patients completed the planned TRT, with the radiotherapy period being extended to .30 days in only one of these patients, suggesting that a lower incidence of severe myelosuppression resulted in a shorter time to completion of TRT in elderly LD-SCLC patients. Moreover, although an age-specific subset analysis in the previous Phase III study revealed that treatment-related death occurred much more often among elderly patients than younger patients (10% in patients aged 70 years or older vs. 1% in younger patients, P ¼ 0.01) (8), treatment-related death was not observed in our study. These results thus suggest that the treatment protocol described here is more feasible than standard chemoradiotherapy for elderly patients with LD-SCLC. In the present study, all 11 evaluable patients showed a response. However, eight patients manifested recurrence, with the median PFS and OS being 11.5 and 17.0 months, respectively. Although it is difficult to evaluate efficacy of the treatment regimen at this stage because of the small number of patients, the relatively short OS may be due to the fact that second-line chemotherapy after recurrence was administered in only two patients. Further research with a larger sample size is thus warranted to evaluate the efficacy of our chemoradiotherapy regimen for elderly LD-SCLC patients.
Elderly patients experience greater treatment toxicity as a result of preexisting illnesses, reduced drug clearance, and limited bone marrow reserve. Physicians should thus be more cautious when monitoring the effects of therapy in elderly patients. Future studies should focus on ways to reduce toxicity in elderly patients with LD-SCLC. Although chemoradiotherapy has a central role in the treatment of patients with LD-SCLC, determination of the optimal treatment for elderly patients with this disease will require additional research.
